

Patient preference for tivozanib hydrochloride or sunitinib in the treatment of metastatic renal cell carcinoma (mRCC): TAURUS study design

Bernard Escudier,¹ Lori Steelman,² Dajana Cesic,² Anna Berkenblit²

¹Institut Gustave Roussy, Villejuif, France; ²AVEO Oncology, Cambridge, MA, USA

Background

- Vascular endothelial growth factor receptors (VEGFRs) play a critical role during tumor angiogenesis via the promotion of endothelial cell proliferation, migration, and survival¹
- Most cases of renal cell carcinoma (RCC) are characterized by a loss of function of the von Hippel-Lindau tumor suppressor gene, which results in an increase in expression of vascular endothelial growth factor (VEGF) and a subsequent increase in tumor angiogenesis²
- Tivozanib hydrochloride (tivozanib) is a potent and selective inhibitor of VEGFRs 1, 2, and 3³
- Previous Phase II and Phase III studies have demonstrated the efficacy and safety of tivozanib in patients with mRCC^{4,5}
- Currently, sunitinib is a commonly used first-line treatment in patients with mRCC⁶
- With the availability of multiple approved therapies for mRCC, treatment choices may be influenced by the adverse event profiles of different therapies
- Patient preference may be an important tool to help patients and physicians in selecting an appropriate treatment⁷
- The goal of this study is to investigate the patient treatment preference for tivozanib or sunitinib for the treatment of mRCC

Key Eligibility Criteria

Inclusion Criteria


- Unresectable mRCC
- Histologically or cytologically confirmed RCC of any histology
- Patients with or without prior nephrectomy
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria

- Any prior systemic therapy for treatment of mRCC (including investigational or licensed drugs that target VEGF or VEGF receptors/pathway, or are mammalian target of rapamycin [mTOR] inhibitors)
- Central nervous system malignancies or metastases
- Significant hematologic, gastrointestinal, thromboembolic, vascular, bleeding, or coagulation disorders
- Significant serum chemistry or urinalysis abnormalities
- Significant cardiovascular disease
 - Uncontrolled hypertension
 - Myocardial infarction or severe angina within 6 months prior to administration of first dose of study drug
- Corrected QT interval of >480 msec using Bazett's formula
- Currently active second primary malignancy

Study Design

- Phase II, randomized, double-blind, multinational, multicenter, two-arm crossover study
- One hundred and sixty patients in Western Europe and the United States
- Patients are stratified for ECOG score (0 vs 1) and histology (clear cell vs non-clear cell) and then randomized 1:1 to one of two treatment arms
- Patients randomized to Arm 1 will receive 1.5 mg oral tivozanib daily on a 3 weeks on/1 week off schedule for 12 weeks (2 cycles) followed by 50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks (2 cycles)
- Patients randomized to Arm 2 will receive 50 mg oral sunitinib daily on a 4 weeks on/2 weeks off schedule for 12 weeks (2 cycles) followed by 1.5 mg oral tivozanib daily on a 3 weeks on/1 week off schedule for 12 weeks (3 cycles)
- Patients will receive double-blinded (over-encapsulated) tivozanib and sunitinib
 - Over-encapsulated placebo will be given during the treatment off-weeks in order to maintain the blind
- There will be a 1-week washout period, in addition to the treatment off-week(s), between the two treatment periods, as shown in **Figure 1**



ECOG, Eastern Cooperative Oncology Group.

- Upon completion of the first 12 weeks of study treatment, all patients will have a tumor assessment and will be informed of their disease assessment result
- Assessment of adverse events (AEs) will be done to establish a baseline AE profile prior to initiation of Drug 2
- All patients are planned to continue the study and to cross over to the second treatment period regardless of their tumor response
 - However, patients with a significant clinical response may continue receiving the same treatment as during the first 12 weeks if the patient prefers it. The patient will continue treatment open-label off the study (sunitinib) or as part of a separate, long-term follow-up study (tivozanib)

- Patients with controlled disease or progressive disease (PD) at the end of the first 12-week treatment period will remain blinded and will cross over as planned to the second treatment for 12 weeks, following the washout period
- Patients who experience PD or unacceptable toxicities during the first treatment period may withdraw early and cross over once toxicities have resolved
- At the end of the study, further treatment is at the discretion of the investigator and patient preference

Dose Interruption and Reduction

- Patients with clinically significant Grade 3/4 AEs that are assessed as being study drug related by the investigator should have their dose interrupted to allow for resolution of toxicities to baseline
- Upon resolution of toxicities, dosing may resume at the initial dose or a reduced dose at the investigator's discretion
- Dose reduction to 1.0 mg/day for tivozanib and to 37.5 mg/day for sunitinib will be allowed
 - Once a dose is reduced, it may not be re-escalated
- Hypertension must be treated with antihypertensive drugs prior to dose reduction

Study Objectives

Primary Objective

- To compare patient treatment preference of tivozanib vs sunitinib

Secondary Objectives

- To compare overall safety and tolerability
- To assess the frequency of dose modifications
- To evaluate quality of life (QoL), including kidney-specific symptoms and fatigue

Exploratory

- To assess anti-tumor activity of tivozanib and sunitinib at 12 weeks
- To compare progression-free survival (PFS) at 25 weeks
- To assess QoL using the Functional Assessment of Cancer Therapy-Anti-Angiogenic (FACT-AntiA) questionnaire

Criteria for Evaluation and Statistical Analysis

Patient Treatment Preference

- A questionnaire will be used to document patient treatment preference and reason(s) at the end of the 25-week treatment period. After the questionnaire is completed, the patients will be unblinded and informed of the result of the end-of-treatment disease assessment

Efficacy

- Response Evaluation Criteria In Solid Tumors (version 1.1) will be used to assess disease status
- Radiology assessments will be performed after the end of each 12-week period
- Patients who withdraw early from either treatment period will have their disease status assessed immediately

Safety

- National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0) will be used for grading toxicities
- Patients will be monitored for occurrence of AEs from the time of signing the informed consent form throughout study treatment and at the 30-day post-treatment safety visit

Quality of Life

- The Functional Assessment of Cancer Therapy-Kidney Symptom Index-Disease Related Symptoms (FKSI-DRS), EQ-5D, Functional Assessment of Chronic Illness Therapy-Diarrhea (FACIT-D), FACIT-Fatigue, and FACT-AntiA questionnaires will be used throughout the study to measure patients' health-related QoL

Statistical Methods

- The proportion of patients who prefer tivozanib will be calculated and presented along with the 95% confidence interval based on the exact binomial distribution
- The reason(s) for treatment preference also will be reported for each arm
- The health-related QoL questionnaires also will be summarized and compared between arms using analysis of variance. The analysis regarding the FACT-AntiA will be exploratory
- Safety analyses will be based on the patients who receive at least one dose of either tivozanib or sunitinib
 - The primary safety analyses will be conducted on the first 12-week treatment period of the study
 - Analyses of safety data after the first 12 weeks will be exploratory
- The safety endpoints include study drug exposure, incidence of AEs, vital signs, clinical laboratory parameters, electrocardiogram measurements, and ECOG performance status
- Study drug modifications and interruptions will be compared between the two arms
- Anti-tumor activity and rate of PFS will be analyzed in the intent-to-treat population and summarized descriptively
- No interim analyses are planned for this study. Ongoing safety assessments will be performed by the sponsor throughout the trial

Discussion

- **In a Phase III clinical trial, tivozanib was well tolerated, with superior efficacy (improved PFS and objective response rate), lower rates of off-target toxicity, and fewer dose adjustments compared with sorafenib in mRCC patients**
- **This Phase II trial is the first, direct comparison of tivozanib vs sunitinib in the same study population, e.g. first-line mRCC**
- Enrollment of patients has recently begun

References

1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med* 2003;9:669–679.
2. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. *Lancet* 2007;370:2103–2111.
3. Nakamura K, Taguchi E, Miura T et al. KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. *Cancer Res* 2006;66:9134–9142.
4. Nosov DA, Esteves B, Lipatov ON et al. Tivozanib activity and safety of tivozanib (AV951) in a Phase II randomized discontinuation trial in patients with renal cell carcinoma. *J Clin Oncol* 2012;30:1678–1685.
5. Motzer RJ, Eisen T, Bondarenko IN et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial. *J Clin Oncol* 2012;30(suppl; abstr 4501).
6. National Comprehensive Cancer Network. *NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer* V2.2012. http://www.nccn.org/professionals/physician_gls/pdf/kidney. Accessed July 2012.
7. Escudier B, Porta C, Bono P et al. Patient preference between pazopanib and sunitinib: Results of a randomized, double-blind, placebo-controlled, crossover study in patients with metastatic renal cell carcinoma (mRCC) (PISCES study – NCT01064310). Presented at the American Society of Clinical Oncology Annual Meeting; June 1–5, 2012; Chicago, IL. Abstract CRA4502.

Acknowledgments

This study was supported by AVEO Oncology and Astellas. AVEO Oncology and Astellas are parties to a collaboration agreement for the co-development of tivozanib hydrochloride. Editorial assistance was provided by Justin Potuzak, PhD, Chameleon Communications International, and was funded by AVEO Oncology and Astellas.

POSTER PRESENTED AT THE 2012 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) ANNUAL MEETING; VIENNA, AUSTRIA; SEPTEMBER 28–OCTOBER 2, 2012.

Corresponding author: Bernard Escudier (Bernard.Escudier@igr.fr)